In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium
Antimicrobial Agents and Chemotherapy · 04.06.2025 · 69 (6)
DOI: 10.1128/aac.01913-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.06.2025. Verfasst von Enrico Garbe und 5 weiteren Autor:innen. Beteiligte Einrichtung: (Epi-)Genetic Regulation of Fungal Virulence, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, German…. Hauptthemen laut MEDLINE: Terbinafine, Fusarium, Antifungal Agents, Natamycin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Freistaat Thüringen, Robert Koch Institut.
Abstract (Originalsprache)
The genus Fusarium includes several trans-kingdom pathogens, infecting plants, animals, and humans, with widespread occurrence. Invasive Fusarium infections are often destructive due to their prevalence in critically ill patients. Furthermore, severe superficial infections, like keratitis or endophthalmitis with potential loss of vision, are rising in incidence globally. Infections are difficult to treat due to the intrinsic resistance of Fusarium against echinocandins and often high minimal inhibitory concentrations (MICs) for azoles. In this article, we assessed the in vitro activity of the novel antifungals olorofim, manogepix, rezafungin, and ibrexafungerp, as well as the established but nonstandard drugs, natamycin and terbinafine, against a large set of molecularly identified clinical Fusarium isolates via EUCAST microdilution. The tested isolates represent the clinically most relevant species of the F. solani (FSSC), F. oxysporum (FOSC), F. fujikuroi (FFSC), F. incarnatum-equiseti (FIESC), F. dimerum (FDSC), and F. redolens (FRSC) species complexes. While rezafungin and ibrexafungerp showed no effect on the Fusarium spp. tested, a general antifungal susceptibility of Fusarium against natamycin and manogepix was found. Specific profiles were detailed for terbinafine and olorofim. While species from the FDSC, FSSC, and FIESC show high MICs for olorofim, specific susceptibility rates were found for species of the FFSC and FOSC. Furthermore, we report specific susceptibilities for terbinafine against FDSC, FFSC, and FOSC species. These findings of complex- and species-specific olorofim and terbinafine in vitro susceptibilities highlight the need for diagnostics below genus level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- (Epi-)Genetic Regulation of Fungal Virulence, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
- Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany.
- National Reference Center for Invasive Fungal Infections (NRZMyk), Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
ORCID-Profile: Enrico Garbe, Alexander Maximilian Aldejohann, Slavica Janevska
Förderung
- Freistaat Thüringen
- Robert Koch Institut
Zitieren
APA
Garbe, E., Ullah, A., Aldejohann, A. M., Kurzai, O., Janevska, S., & Walther, G. (2025). In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium. Antimicrobial Agents and Chemotherapy, 69(6). https://doi.org/10.1128/aac.01913-24
Vancouver
Garbe E, Ullah A, Aldejohann AM, Kurzai O, Janevska S, Walther G. In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium. Antimicrobial Agents and Chemotherapy. 2025;69(6). doi:10.1128/aac.01913-24
BibTeX
@article{Garbe2025,
author = {Garbe, Enrico and Ullah, Ahsan and Aldejohann, Alexander Maximilian and Kurzai, Oliver and Janevska, Slavica and Walther, Grit},
title = {In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {6},
doi = {10.1128/aac.01913-24}
}
EUVIMED